Severity of Sarcopenia in Parkinson's Disease

NCT ID: NCT07014514

Last Updated: 2025-11-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

77 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-06-20

Study Completion Date

2025-10-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to examine the severity of sarcopenia in Parkinson's disease patients. Patients between the ages of 40-75 who have been diagnosed with Parkinson's disease by a neurologist and healthy individuals with similar demographic characteristics will be included in the study as a control group. The staging of Parkinson's patients will be done with the Modified Hoehn and Yahr Scale, and the severity of the disease will be done with the Unified Parkinson's Disease Rating Scale. Within the scope of the study, anterior thigh thicknesses of individuals with Parkinson's disease will be evaluated with ultrasonography. Sarcopenia severity will be determined with the ISarcoPRM algorithm using the ultrasonographic evaluations of the individuals. It is planned to include 80 Parkinson's patients in the study. Parkinson's patients between stages 1-3 according to the Modified Hoehn and Yahr Scale will be included in the study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study Group

Patients with Parkinson's Disease

No interventions assigned to this group

Control Group

Healthy individuals with similar demographic characteristics

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Score between 24 and 30 on the Mini Mental State Examination
* Be diagnosed with Parkinson's Disease by a neurologist
* Stage 1-3 on the Modified Hoehn and Yahr Scale

Exclusion Criteria

* Inability to communicate verbally
* Elderly people with severe visual impairment, neurological disorders in addition to Parkinson's and/or congestive heart failure
* Older adults in whom exercise is not recommended
Minimum Eligible Age

40 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ankara University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Büşra Seçkinoğulları Korkusuz

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Süleyman Korkusuz, PhD

Role: STUDY_CHAIR

Atılım University

Ayla Fil Balkan, Assoc Prof

Role: STUDY_CHAIR

Hacettepe University

Gül Yalçın Çakmaklı, Assoc Prof

Role: STUDY_CHAIR

Hacettepe University

Büşra Seçkinoğulları Korkusuz, PhD

Role: PRINCIPAL_INVESTIGATOR

Ankara University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Atılım University

Ankara, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

References

Explore related publications, articles, or registry entries linked to this study.

Studenski SA, Peters KW, Alley DE, Cawthon PM, McLean RR, Harris TB, Ferrucci L, Guralnik JM, Fragala MS, Kenny AM, Kiel DP, Kritchevsky SB, Shardell MD, Dam TT, Vassileva MT. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci. 2014 May;69(5):547-58. doi: 10.1093/gerona/glu010.

Reference Type RESULT
PMID: 24737557 (View on PubMed)

Kara M, Kaymak B, Frontera W, Ata AM, Ricci V, Ekiz T, Chang KV, Han DS, Michail X, Quittan M, Lim JY, Bean JF, Franchignoni F, Ozcakar L. Diagnosing sarcopenia: Functional perspectives and a new algorithm from the ISarcoPRM. J Rehabil Med. 2021 Jun 21;53(6):jrm00209. doi: 10.2340/16501977-2851.

Reference Type RESULT
PMID: 34121127 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

E-59394181-604.01-112205

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Posture Exercises in Parkinson's Disease
NCT06848257 ENROLLING_BY_INVITATION NA